[go: up one dir, main page]

IN2012DN05014A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05014A
IN2012DN05014A IN5014DEN2012A IN2012DN05014A IN 2012DN05014 A IN2012DN05014 A IN 2012DN05014A IN 5014DEN2012 A IN5014DEN2012 A IN 5014DEN2012A IN 2012DN05014 A IN2012DN05014 A IN 2012DN05014A
Authority
IN
India
Prior art keywords
moieties
vegf
ectodomain
antagonize
receptors
Prior art date
Application number
Other languages
English (en)
Inventor
Joseph Schlessinger
Yan Yang
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IN2012DN05014A publication Critical patent/IN2012DN05014A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
IN5014DEN2012 2009-12-29 2010-12-20 IN2012DN05014A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29078909P 2009-12-29 2009-12-29
PCT/US2010/061296 WO2011090648A2 (en) 2009-12-29 2010-12-20 Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2012DN05014A true IN2012DN05014A (ja) 2015-10-02

Family

ID=44307462

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5014DEN2012 IN2012DN05014A (ja) 2009-12-29 2010-12-20

Country Status (14)

Country Link
US (1) US20130071397A1 (ja)
EP (1) EP2519253A4 (ja)
JP (1) JP2013515776A (ja)
KR (1) KR20120115348A (ja)
CN (1) CN102724996A (ja)
AU (1) AU2010343193A1 (ja)
BR (1) BR112012016309A2 (ja)
CA (1) CA2785723A1 (ja)
IL (1) IL220147A0 (ja)
IN (1) IN2012DN05014A (ja)
MX (1) MX2012007745A (ja)
RU (1) RU2012132470A (ja)
SG (1) SG181495A1 (ja)
WO (1) WO2011090648A2 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155238B1 (en) 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
TWI596113B (zh) 2012-07-25 2017-08-21 塞爾德克斯醫療公司 抗ｋｉｔ抗體及其用途
AU2014342065B2 (en) * 2013-11-01 2019-01-03 Atrium Medical Corporation Positioning agent and method of using the same
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
CN104356226B (zh) * 2014-11-04 2017-03-29 青岛海兰深生物科技有限公司 一种检测血浆免疫标志物‑vegfr1自身抗体的抗原多肽及应用
CN108285484B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148135B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
GB201612520D0 (en) * 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3063719A1 (en) 2017-05-19 2018-11-22 The Regents Of The University Of California Antibody chemically induced dimerizer (abcid) as molecular switches for regulating cellular therapies
WO2018234543A1 (en) 2017-06-23 2018-12-27 Baxalta Incorporated PURIFICATION OF FACTOR VIII SUBSPECIES
WO2024155689A1 (en) * 2023-01-17 2024-07-25 Yale University Compounds and methods for inhibiting type-iii receptor tyrosine kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
PT1487856E (pt) * 2002-03-04 2010-09-29 Imclone Llc Anticorpos humanos específicos para kdr e usos destes
EP2155238B1 (en) * 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도

Also Published As

Publication number Publication date
KR20120115348A (ko) 2012-10-17
IL220147A0 (en) 2012-07-31
CA2785723A1 (en) 2011-07-28
WO2011090648A2 (en) 2011-07-28
SG181495A1 (en) 2012-07-30
EP2519253A4 (en) 2013-08-07
AU2010343193A1 (en) 2012-06-21
RU2012132470A (ru) 2014-02-10
US20130071397A1 (en) 2013-03-21
WO2011090648A3 (en) 2012-01-05
MX2012007745A (es) 2012-11-23
CN102724996A (zh) 2012-10-10
EP2519253A2 (en) 2012-11-07
JP2013515776A (ja) 2013-05-09
BR112012016309A2 (pt) 2017-04-18

Similar Documents

Publication Publication Date Title
IN2012DN05014A (ja)
MX2011011825A (es) Anticuerpos humanizados para axl.
GB201017345D0 (en) Receptor antagonists
MX2010005031A (es) Anticuerpos de axl.
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
SMT201600216B (it) Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina
PH12013501096B1 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
MX2011008500A (es) Moduladores del receptor tipo toll y tratamiento de enfermedades.
MX356085B (es) Moduladores novedosos.
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
EP2560684A4 (en) FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
IL207130A0 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BRPI1013821A2 (pt) piridinas substituídas como antagonistas de ccr3.
UA104626C2 (ru) Анти-vegf антитело и его применение
GB2460597B8 (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
IN2012DN00580A (ja)
WO2010070658A3 (en) Improved process for the preparation of endothelin receptor antagonists
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
EA201171074A1 (ru) Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
WO2007014263A3 (en) Octahydroisoquinoline compounds as opioid receptor modulators
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
UA107596C2 (uk) Виділений поліпептид, який зв'язується з рецептором інсуліноподібного фактора росту 1
MX337106B (es) Antagonistas no competitivos de receptores nicotinicos.